Efficacy and Safety of Oral Gonadotropin-releasing Hormone Antagonists in Moderate-to-severe Endometriosis-associated Pain: a Systematic Review and Network Meta-analysis

Overview

Journal Arch Gynecol Obstet

Specialty Gynecology & Obstetrics

Date 2023 Jan 19

PMID 36656435

Authors

Lingli Xin

Yinghao Ma

Mei Ye

Ling Chen

Fuzhou Liu

Qingxiang Hou

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this NMA is to comprehensively analyze evidence of oral GnRH antagonist in the treatment of moderate-to-severe endometriosis-associated pain.

Methods: Literature searching was performed to select eligible studies published prior to April 2022 in PubMed, Cochrane, Embase and Web of Science. Randomized controlled trials involving patients who suffered from moderate-to-severe endometriosis-associated pain and treated with oral nonpeptide GnRH antagonists or placebo were included.

Results: Elagolix 400 mg and ASP1707 15 mg were most efficient in reducing pelvic pain, dysmenorrhea and dyspareunia. Relugolix 40 mg was best in reducing the analgesics use. The rates of any TEAEs and TEAEs-related discontinuation were highest in relugolix 40 mg and elagolix 250 mg, respectively, while rates of hot flush and headache were highest in relugolix 40 mg and elagolix 150 mg. Significantly decreased spinal BMD was observed in elagolix 250 mg.

Conclusion: Oral GnRH antagonists were effective in endometriosis-associated pain in 12w, and most of the efficiency and safety outcomes were expressed in a dose-dependent manner, but linzagolix 75 mg was an exception.

Citing Articles

Efficacy of GnRH antagonists in the treatment of uterine fibroids: a meta-analysis.

Sanchez Martin M, Huerga Lopez C, Cristobal Garcia I, Cristobal Quevedo I Arch Gynecol Obstet. 2025; .

PMID: 39821450 DOI: 10.1007/s00404-025-07932-9.

Progesterone resistance in endometriosis: A pathophysiological perspective and potential treatment alternatives.

Tang H, Lin T, Wu M, Tsai S Reprod Med Biol. 2024; 23(1):e12588.

PMID: 38854774 PMC: 11157498. DOI: 10.1002/rmb2.12588.

Proposal for targeted, neo-evolutionary-oriented secondary prevention of early-onset endometriosis and adenomyosis. Part II: medical interventions.

Vercellini P, Bandini V, Vigano P, Ambruoso D, Cetera G, Somigliana E Hum Reprod. 2023; 39(1):18-34.

PMID: 37951241 PMC: 11639102. DOI: 10.1093/humrep/dead206.

References

Carr B, Giudice L, Dmowski W, OBrien C, Jiang P, Burke J . Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study. J Endometr Pelvic Pain Disord. 2018; 5(3):105-115. PMC: 6166402. DOI: 10.5301/je.5000157. View

Leyland N, Estes S, Lessey B, Advincula A, Taylor H . A Clinician's Guide to the Treatment of Endometriosis with Elagolix. J Womens Health (Larchmt). 2020; 30(4):569-578. PMC: 8064963. DOI: 10.1089/jwh.2019.8096. View

Vercellini P, Buggio L, Frattaruolo M, Borghi A, Dridi D, Somigliana E . Medical treatment of endometriosis-related pain. Best Pract Res Clin Obstet Gynaecol. 2018; 51:68-91. DOI: 10.1016/j.bpobgyn.2018.01.015. View

DHooghe T, Fukaya T, Osuga Y, Besuyen R, Lopez B, Holtkamp G . Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study. Hum Reprod. 2019; 34(5):813-823. PMC: 6505452. DOI: 10.1093/humrep/dez028. View

Cumpston M, Li T, Page M, Chandler J, Welch V, Higgins J . Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019; 10:ED000142. PMC: 10284251. DOI: 10.1002/14651858.ED000142. View

Taylor H, Giudice L, Lessey B, Abrao M, Kotarski J, Archer D . Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. N Engl J Med. 2017; 377(1):28-40. DOI: 10.1056/NEJMoa1700089. View

Gao X, Outley J, Botteman M, Spalding J, Simon J, Pashos C . Economic burden of endometriosis. Fertil Steril. 2006; 86(6):1561-72. DOI: 10.1016/j.fertnstert.2006.06.015. View

Ferrero S, Barra F, Leone Roberti Maggiore U . Current and Emerging Therapeutics for the Management of Endometriosis. Drugs. 2018; 78(10):995-1012. DOI: 10.1007/s40265-018-0928-0. View

Donnez J, Taylor H, Taylor R, Akin M, Tatarchuk T, Wilk K . Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial. Fertil Steril. 2020; 114(1):44-55. DOI: 10.1016/j.fertnstert.2020.02.114. View

10.

Osuga Y, Seki Y, Tanimoto M, Kusumoto T, Kudou K, Terakawa N . Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2020; 115(2):397-405. DOI: 10.1016/j.fertnstert.2020.07.055. View

11.

Dababou S, Garzon S, Lagana A, Ferrero S, Evangelisti G, Noventa M . Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas. Expert Opin Investig Drugs. 2021; 30(9):903-911. DOI: 10.1080/13543784.2021.1957830. View

12.

Schlaff W, Ackerman R, Al-Hendy A, Archer D, Barnhart K, Bradley L . Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. N Engl J Med. 2020; 382(4):328-340. DOI: 10.1056/NEJMoa1904351. View

13.

Giudice L . Clinical practice. Endometriosis. N Engl J Med. 2010; 362(25):2389-98. PMC: 3108065. DOI: 10.1056/NEJMcp1000274. View

14.

Surrey E, Taylor H, Giudice L, Lessey B, Abrao M, Archer D . Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies. Obstet Gynecol. 2018; 132(1):147-160. DOI: 10.1097/AOG.0000000000002675. View

15.

Della Corte L, Di Filippo C, Gabrielli O, Reppuccia S, La Rosa V, Ragusa R . The Burden of Endometriosis on Women's Lifespan: A Narrative Overview on Quality of Life and Psychosocial Wellbeing. Int J Environ Res Public Health. 2020; 17(13). PMC: 7370081. DOI: 10.3390/ijerph17134683. View

16.

Barra F, Seca M, Della Corte L, Giampaolino P, Ferrero S . Relugolix for the treatment of uterine fibroids. Drugs Today (Barc). 2019; 55(8):503-512. DOI: 10.1358/dot.2019.55.8.3020179. View

17.

Eskenazi B, Warner M . Epidemiology of endometriosis. Obstet Gynecol Clin North Am. 1997; 24(2):235-58. DOI: 10.1016/s0889-8545(05)70302-8. View

18.

Osuga Y, Seki Y, Tanimoto M, Kusumoto T, Kudou K, Terakawa N . Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results. BMC Womens Health. 2021; 21(1):250. PMC: 8218467. DOI: 10.1186/s12905-021-01393-3. View

19.

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

20.

Diamond M, Carr B, Dmowski W, Koltun W, OBrien C, Jiang P . Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci. 2013; 21(3):363-71. DOI: 10.1177/1933719113497292. View